Brilinta, the trade name for ticagrelor, is used for the prevention of thrombotic events in patients with acute coronary syndrome or myocardial infarction with ST elevation.
Brilinta (ticagrelor) is a prescription medicine intended for people who experience a heart attack or severe chest pain due to lack of oxygen. The drug is often prescribed with aspirin to prevent platelets sticking together and forming a blood clot that could block blood flow to the heart.
In 2013, AstraZeneca announced its plan to initiate two new studies on Brilinta. The first study will compare the use of Brilinta for the prevention of major vascular events in patients with acute ischemic stroke or transient ischemic attack with aspirin, while the second study will evaluate Brilinta for the long-term prevention of major vascular events in patients suffering from type II diabetes at high cardiovascular risk.